Here’s a breakdown of teh provided text,summarizing the key information:
Main Topic: A new trial (MAGIC trial) investigating contrast sensitivity as a functional test in patients with nonproliferative diabetic retinopathy (NPDR) and retinal nonperfusion.
Key People: Dante J. Pieramici, MD
Trial Details (MAGIC Trial):
purpose: To assess the impact of Vabysmo (faricimab) on retinal nonperfusion.
Design: Randomized trial.
Arms:
Monthly Vabysmo for 1 year, then quarterly treatments. Observation for 1 year, then faricimab in the second year.
Primary Endpoint: Change in area of retinal nonperfusion (measured by optos widefield angiography).
why Contrast sensitivity Matters:
Conventional visual acuity tests may not detect problems until diabetic retinopathy is advanced.
Contrast sensitivity is a more effective functional endpoint as it can detect subtle vision changes earlier.
* New methods allow for quick and effective measurement of contrast sensitivity.
Source: Presentation by Dante J. pieramici at Clinical Trials at the Summit (June 21,2025,Las Vegas).
Disclosure: Healio could not confirm any relevant financial disclosures for the speaker at the time of publication.
